Conversion surgery for advanced pancreatic cancer

While primarily unresectable locally advanced pancreatic cancer (LAPC) used to be an indication for palliative therapy, a strategy of neoadjuvant therapy (NAT) and conversion surgery is being increasingly used after more effective chemotherapy regimens have become available for pancreatic ductal ade...

Full description

Saved in:
Bibliographic Details
Main Authors: Hank, Thomas (Author) , Strobel, Oliver (Author)
Format: Article (Journal)
Language:English
Published: 12 November 2019
In: Journal of Clinical Medicine
Year: 2019, Volume: 8, Issue: 11
ISSN:2077-0383
DOI:10.3390/jcm8111945
Online Access:Verlag, Volltext: https://doi.org/10.3390/jcm8111945
Verlag: https://www.mdpi.com/2077-0383/8/11/1945
Get full text
Author Notes:Thomas Hank, and Oliver Strobel

MARC

LEADER 00000caa a2200000 c 4500
001 168791981X
003 DE-627
005 20230427215351.0
007 cr uuu---uuuuu
008 200121s2019 xx |||||o 00| ||eng c
024 7 |a 10.3390/jcm8111945  |2 doi 
035 |a (DE-627)168791981X 
035 |a (DE-599)KXP168791981X 
035 |a (OCoLC)1341298554 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hank, Thomas  |d 1985-  |e VerfasserIn  |0 (DE-588)1071498525  |0 (DE-627)825952271  |0 (DE-576)433115610  |4 aut 
245 1 0 |a Conversion surgery for advanced pancreatic cancer  |c Thomas Hank, and Oliver Strobel 
264 1 |c 12 November 2019 
300 |a 18 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 21.01.2020 
520 |a While primarily unresectable locally advanced pancreatic cancer (LAPC) used to be an indication for palliative therapy, a strategy of neoadjuvant therapy (NAT) and conversion surgery is being increasingly used after more effective chemotherapy regimens have become available for pancreatic ductal adenocarcinoma. While high-level evidence from prospective studies is still sparse, several large retrospective studies have recently reported their experience with NAT and conversion surgery for LAPC. This review aims to provide a current overview about different NAT regimens, conversion rates, survival outcomes and determinants of post-resection outcomes, as well as surgical strategies in the context of conversion surgery after NAT. FOLFIRINOX is the predominant regimen used and associated with the highest reported conversion rates. Conversion rates considerably vary between less than 5% and more than half of the study population with heterogeneous long-term outcomes, owing to a lack of intention-to-treat analyses in most studies and a high heterogeneity in resectability criteria, treatment strategies, and reporting among studies. Since radiological criteria of local resectability are no longer applicable after NAT, patients without progressive disease should undergo surgical exploration. Surgery after NAT has to be aimed at local radicality around the peripancreatic vessels and should be performed in expert centers. Future studies in this rapidly evolving field need to be prospective, analyze intention-to-treat populations, report stringent and objective inclusion criteria and criteria for resection. Innovative regimens for NAT in combination with a radical surgical approach hold high promise for patients with LAPC in the future. 
650 4 |a conversion surgery 
650 4 |a FOLFIRINOX 
650 4 |a locally advanced pancreatic cancer 
650 4 |a neoadjuvant therapy 
650 4 |a pancreatic cancer 
700 1 |a Strobel, Oliver  |d 1974-  |e VerfasserIn  |0 (DE-588)123658977  |0 (DE-627)706385101  |0 (DE-576)293812357  |4 aut 
773 0 8 |i Enthalten in  |t Journal of Clinical Medicine  |d Basel : MDPI, 2012  |g 8(2019,11) Artikel-Nummer 1945, 18 Seiten  |h Online-Ressource  |w (DE-627)718632478  |w (DE-600)2662592-1  |w (DE-576)365782718  |x 2077-0383  |7 nnas  |a Conversion surgery for advanced pancreatic cancer 
773 1 8 |g volume:8  |g year:2019  |g number:11  |g extent:18  |a Conversion surgery for advanced pancreatic cancer 
856 4 0 |u https://doi.org/10.3390/jcm8111945  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2077-0383/8/11/1945  |x Verlag 
951 |a AR 
992 |a 20200121 
993 |a Article 
994 |a 2019 
998 |g 123658977  |a Strobel, Oliver  |m 123658977:Strobel, Oliver  |d 910000  |d 910200  |e 910000PS123658977  |e 910200PS123658977  |k 0/910000/  |k 1/910000/910200/  |p 2  |y j 
998 |g 1071498525  |a Hank, Thomas  |m 1071498525:Hank, Thomas  |d 910000  |d 910200  |e 910000PH1071498525  |e 910200PH1071498525  |k 0/910000/  |k 1/910000/910200/  |p 1  |x j 
999 |a KXP-PPN168791981X  |e 3577739118 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.3390/jcm8111945"],"eki":["168791981X"]},"title":[{"title":"Conversion surgery for advanced pancreatic cancer","title_sort":"Conversion surgery for advanced pancreatic cancer"}],"recId":"168791981X","note":["Gesehen am 21.01.2020"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"12 November 2019"}],"name":{"displayForm":["Thomas Hank, and Oliver Strobel"]},"person":[{"roleDisplay":"VerfasserIn","family":"Hank","given":"Thomas","role":"aut","display":"Hank, Thomas"},{"display":"Strobel, Oliver","role":"aut","given":"Oliver","roleDisplay":"VerfasserIn","family":"Strobel"}],"physDesc":[{"extent":"18 S."}],"relHost":[{"recId":"718632478","pubHistory":["1.2012 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"MDPI","dateIssuedKey":"2012","publisherPlace":"Basel","dateIssuedDisp":"2012-"}],"part":{"text":"8(2019,11) Artikel-Nummer 1945, 18 Seiten","issue":"11","volume":"8","year":"2019","extent":"18"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Conversion surgery for advanced pancreatic cancerJournal of Clinical Medicine","note":["Gesehen am 12.06.20"],"title":[{"title_sort":"Journal of Clinical Medicine","title":"Journal of Clinical Medicine","subtitle":"open access journal"}],"id":{"issn":["2077-0383"],"eki":["718632478"],"zdb":["2662592-1"]}}]} 
SRT |a HANKTHOMASCONVERSION1220